GO
Loading...

Enter multiple symbols separated by commas

Stocks Bayer AG

More

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Actavis Plc holds the commercial license to the device, Liletta. Actavis and Medicines360 expect the device to be available for use in the United States by the second quarter of 2015.. The Actavis device will compete in the $1 billion global market for UIDs, said Michael WaterHouse, an analyst at brokerage Morningstar.

  • Earnings, Yellen help Europe shares end higher Thursday, 26 Feb 2015 | 11:43 AM ET

    European equities rallied on Thursday, closing nearly 1 percent higher as investors reacted to a raft of corporate earnings and fresh economic data.

  • Stars aligned for us: Bayer CEO Thursday, 26 Feb 2015 | 7:51 AM ET
    Bayer CEO Marijn Dekkers

    New drugs and increased spending on research and development mean the "stars are aligned" for German drugs giant Bayer, the firm's CEO said.

  • Bayer is 'focusing on life sciences' Thursday, 26 Feb 2015 | 6:00 AM ET
    Bayer is 'focusing on life sciences'

    Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.

  • Bayer R&D budget to increase Thursday, 26 Feb 2015 | 6:00 AM ET
    Bayer R&D budget to increase

    Marijn Dekkers, CEO of Bayer, says the company plans to increase its R&D budget this year, after strong earnings.

  • New Sanofi boss will earn up to 4.2 mln eur a year Friday, 20 Feb 2015 | 1:36 PM ET

    PARIS, Feb 20- Sanofi's new boss Olivier Brandicourt will earn up to 4.2 million euros a year at the drugs group and could pocket 4 million extra as a one-off golden handshake. The pay of the former medical doctor, who is due to take up his new role from April, was revealed in a statement by the French drugs firm on Friday, a day after the 59- year-old Bayer AG executive was...

  • TOKYO, Feb 20- German drugmaker Bayer AG is close to selling its diabetes devices business to KKR-backed Panasonic Healthcare Holdings Co Ltd and the unit could be valued at up to $2.3 billion, Bloomberg news reported. The announcement of the buyout may come as early as Friday, although the talks are ongoing and an agreement may be delayed or fall apart, Bloomberg...

  • PARIS, Feb 19- French drugmaker Sanofi on Thursday named Olivier Brandicourt, a Paris- educated doctor and head of Bayer AG's healthcare arm, as its chief executive officer. Brandicourt had been widely tipped to become Sanofi's new boss, a position that opened when Chris Viehbacher was suddenly sacked last year. "Olivier Brandicourt's strong experience...

  • Feb 10- Regeneron Pharmaceuticals Inc reported better-than-expected fourth-quarter sales, driven by surging demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including...

  • Feb 10- Regeneron Pharmaceuticals Inc reported a nearly 14 percent jump in quarterly profit, driven by strong demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including collaboration...

  • Expirations, drop in hep C drugs hit Merck sales Monday, 27 Oct 2014 | 9:50 AM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.

  • Europe shares close higher on Fed relief, ECB Thursday, 18 Sep 2014 | 11:55 AM ET

    European shares closed higher on Thursday after an important announcement regarding the meetings of the European Central Bank.

  • Bayer plans to float plastics business Thursday, 18 Sep 2014 | 9:54 AM ET

    Germany's largest drugmaker, Bayer, plans to float its plastics business on the stock market and focus on healthcare and crop science.

  • 'Good time' to float plastics business: Bayer CEO Thursday, 18 Sep 2014 | 7:30 AM ET
    'Good time' to float plastics business: Bayer CEO

    Marijn Dekkers,CEO of Bayer, says now is a "good time" to float the company's plastics business and prefers the IPO route.

  • Merck beats forecasts, as newer drugs offset generics Tuesday, 29 Jul 2014 | 10:39 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.

  • Big lobbying dollars flow in engineered food fight Tuesday, 29 Jul 2014 | 4:29 AM ET
    A researcher takes tissue samples from genetically modified corn plants.

    The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.

  • Merck proud to be a US-based company: CEO Wednesday, 4 Jun 2014 | 8:52 AM ET
    Ken Frazier, president and CEO of Merck.

    But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.

  • Early movers: WMT, GM, DTV, T & more Thursday, 15 May 2014 | 7:42 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Which M&A deal is best for shareholders? Monday, 12 May 2014 | 12:44 AM ET

    Which M&A deal represents the best value for shareholders?